Classical and Emerging Biomarkers in Pyridoxine-Dependent Epilepsy (PDE-ALDH7A1): Implications for Early Diagnosis

Muna Abedrabbo1, Safiya Al Yazeedi2, Blair R Leavitt1,3

  • 1Centre for Molecular Medicine and Therapeutics, BC Children's Hospital and the Department of Medical Genetics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.

Biomolecules
|May 4, 2026
PubMed

Insights

Pyridoxine-dependent epilepsy (PDE-ALDH7A1) stems from impaired lysine breakdown, causing neurodevelopmental issues. New, stable biomarkers offer improved diagnostics and potential for better treatments beyond pyridoxine.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Pyridoxine-dependent epilepsy due to ALDH7A1 deficiency (PDE-ALDH7A1) is a rare epileptic encephalopathy.
  • It results from disrupted lysine catabolism, leading to pyridoxal-5'-phosphate (PLP) depletion.
  • Current treatments with pyridoxine control seizures but not neurodevelopmental impairment.

Purpose of the Study:

  • To review lysine catabolism in health and disease.
  • To evaluate diagnostic biomarkers for PDE-ALDH7A1.
  • To discuss novel biomarkers for improved diagnosis and understanding of disease mechanisms.

Main Methods:

  • Literature review of lysine catabolism and PDE-ALDH7A1.
  • Critical evaluation of existing biomarkers (α-AASA, P6C, pipecolic acid).
  • Highlighting novel biomarkers (6-oxo-PIP, 2-OPP, HACA) identified via metabolomics.

Main Results:

  • Classical biomarkers (α-AASA, P6C, pipecolic acid) are unstable and challenging for diagnostics.
  • Novel, stable biomarkers (6-oxo-PIP, 2-OPP, HACA) show promise for newborn screening.
  • These new biomarkers offer mechanistic insights into seizure susceptibility and neurological morbidity.

Conclusions:

  • Advances in biomarker discovery are revolutionizing PDE-ALDH7A1 diagnostics.
  • Novel biomarkers facilitate earlier detection and understanding of disease pathophysiology.
  • This paves the way for developing more effective, mechanism-based therapies for PDE-ALDH7A1.